Long term treatment study of 0.02% STN1013900 ophthalmic solution alone or in combination with either 0.005% Latanoprost ophthalmic solution, or 0.5%Timolol ophthalmic solution in subjects with open angle glaucoma or ocular hypertension

A prospective, open-label, multi-center, randomized, 52-week study evaluating the safety and efficacy of 0.02% STN1013900 ophthalmic solution alone or in combination with either 0.005% Latanoprost ophthalmic solution, or 0.5%Timolol ophthalmic solution in subjects with open angle glaucoma or ocular hypertension

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210125

Enrollment

150

Registered

2021-05-31

Start date

2021-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

POAG, NTG, pseudoexfoliative glaucoma, pigmentary glaucoma or OHT

Interventions

Group 1: 1 drop 0.02% STN1013900 once daily Group 2: 1 drop 0.02% STN1013900 once daily Group 3: 1 drop 0.02% STN1013900 once daily and 1 drop 0.005% Latanoprost Group 4: 1 drop 0.02% STN1013900 once

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 20 years of age or older Diagnosis of POAG, NTG, pseudoexfoliative glaucoma, pigmentary glaucoma or OHT in both eyes Best-corrected visual acuity (BCVA) +0.7 log MAR or better (>= 20/100 Snellen or >= 0.20 in decimal unit) in each eye Willingness and ability to give signed informed consent and follow study instructions

Exclusion criteria

Exclusion criteria: Ophthalmic: Clinically significant ocular disease History of angle closure glaucoma, or narrow angles Previous glaucoma intraocular surgery Refractive surgery in either eye Ocular trauma Ocular infection Any corneal disease Known hypersensitivity to any component of the study drugs, or to topical anesthetic Systemic: Clinically significant systemic disease Participation in any investigational study within 30 days prior to screening Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control

Design outcomes

Primary

Measure	Time frame
Mean diurnal IOP at each visit	—

Contacts

Public ContactKayoko Sakamoto

Santen pharmaceutical co.,ltd

clinical@santen.co.jp+81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026